Went public 8/9/2000 at $9 per share
Filing Range: 6 mil. shares @ $11 to $13
Shares Outstanding: 22.9 mil. shares
Underwriters: Chase H&Q/Robertson Stephens & Co./ Adams Harkness & Hill
Inc./A.G. Edwards & Sons Inc.
Company Counsel: Long Aldridge & Norman LLP
Manager Counsel: Brown & Wood
Auditor: Ernst & Young LLP
Owns and operates a biopharmaceutical company with a technology platform based on the identification of regulatory signals that control the expression of critical genes involved in inflammatory diseases such as atherosclerosis and proliferative diseases such as cancer. The company has developed small-molecule compounds termed vascular protectants, or v-protectants. These v-protectants target regulatory pathways and have established therapeutic efficacy in preclinical models for atherosclerosis and hypercholesterolemia.
William Blair Venture Partners
Alliance Technology Ventures
Domain Associates LLC
LiveOak Equity Partners
New York Life Venture Capital Group
Community Technology Fund
SENMED Medical Ventures
Pacific Horizon Ventures LLC
Intelligent Systems Corp.
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 08/01/1996 4 Early Stage 5600.0
2 08/24/1998 10 Later Stage 6000.0
3 04/13/1999 18 Expansion 22389.3
4 08/23/1999 13 Expansion 19988.0
5 03/09/2000 1 Expansion 100.0
(Data in $ millions)
Total Revenues: $5.8
Net Income: -6.0